Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 2.04
PTLA's Cash-to-Debt is ranked lower than
72% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. PTLA: 2.04 )
Ranked among companies with meaningful Cash-to-Debt only.
PTLA' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.04  Med: No Debt Max: No Debt
Current: 2.04
2.04
No Debt
Equity-to-Asset 0.43
PTLA's Equity-to-Asset is ranked lower than
77% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. PTLA: 0.43 )
Ranked among companies with meaningful Equity-to-Asset only.
PTLA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.81 Max: 0.91
Current: 0.43
0.36
0.91
Debt-to-Equity 0.98
PTLA's Debt-to-Equity is ranked lower than
83% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. PTLA: 0.98 )
Ranked among companies with meaningful Debt-to-Equity only.
PTLA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.27  Med: 0.38 Max: 0.99
Current: 0.98
0.27
0.99
Debt-to-EBITDA -0.61
PTLA's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. PTLA: -0.61 )
Ranked among companies with meaningful Debt-to-EBITDA only.
PTLA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.61  Med: -0.32 Max: -0.22
Current: -0.61
-0.61
-0.22
Piotroski F-Score: 3
Altman Z-Score: -1.73
Beneish M-Score: -3.45
WACC vs ROIC
14.66%
2964.36%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -1462.99
PTLA's Operating Margin % is ranked lower than
79% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. PTLA: -1462.99 )
Ranked among companies with meaningful Operating Margin % only.
PTLA' s Operating Margin % Range Over the Past 10 Years
Min: -1882.15  Med: -779.33 Max: 25.46
Current: -1462.99
-1882.15
25.46
Net Margin % -1503.29
PTLA's Net Margin % is ranked lower than
80% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. PTLA: -1503.29 )
Ranked among companies with meaningful Net Margin % only.
PTLA' s Net Margin % Range Over the Past 10 Years
Min: -1876.59  Med: -774.64 Max: 25.61
Current: -1503.29
-1876.59
25.61
ROE % -129.50
PTLA's ROE % is ranked lower than
81% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. PTLA: -129.50 )
Ranked among companies with meaningful ROE % only.
PTLA' s ROE % Range Over the Past 10 Years
Min: -129.5  Med: -42.58 Max: 9.6
Current: -129.5
-129.5
9.6
ROA % -72.48
PTLA's ROA % is ranked lower than
76% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. PTLA: -72.48 )
Ranked among companies with meaningful ROA % only.
PTLA' s ROA % Range Over the Past 10 Years
Min: -72.48  Med: -36.95 Max: 20.67
Current: -72.48
-72.48
20.67
ROC (Joel Greenblatt) % -6475.62
PTLA's ROC (Joel Greenblatt) % is ranked lower than
82% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. PTLA: -6475.62 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PTLA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6475.62  Med: -4328.31 Max: 1029.06
Current: -6475.62
-6475.62
1029.06
3-Year Revenue Growth Rate 19.20
PTLA's 3-Year Revenue Growth Rate is ranked higher than
75% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. PTLA: 19.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PTLA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -58.2  Med: -30.7 Max: 19.2
Current: 19.2
-58.2
19.2
3-Year EBITDA Growth Rate -13.00
PTLA's 3-Year EBITDA Growth Rate is ranked lower than
68% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. PTLA: -13.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PTLA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -78.3 Max: -9.1
Current: -13
3-Year EPS without NRI Growth Rate -14.70
PTLA's 3-Year EPS without NRI Growth Rate is ranked lower than
71% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. PTLA: -14.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PTLA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -9.3
Current: -14.7
GuruFocus has detected 4 Warning Signs with Portola Pharmaceuticals Inc PTLA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PTLA's 30-Y Financials

Financials (Next Earnings Date: 2018-11-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

PTLA Guru Trades in Q3 2017

Leon Cooperman 50,000 sh (New)
Paul Tudor Jones 31,961 sh (+94.66%)
Jim Simons 528,500 sh (+40.11%)
Ken Fisher 61,893 sh (+32.71%)
Joel Greenblatt Sold Out
» More
Q4 2017

PTLA Guru Trades in Q4 2017

Pioneer Investments 107,959 sh (New)
Vanguard Health Care Fund 168,887 sh (New)
Ken Fisher 96,654 sh (+56.16%)
Leon Cooperman Sold Out
Jim Simons 352,800 sh (-33.25%)
Paul Tudor Jones 7,580 sh (-76.28%)
» More
Q1 2018

PTLA Guru Trades in Q1 2018

Leucadia National 15,000 sh (New)
Vanguard Health Care Fund 2,913,937 sh (+1625.38%)
Pioneer Investments 174,859 sh (+61.97%)
Jim Simons 366,400 sh (+3.85%)
Ken Fisher 96,654 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2018

PTLA Guru Trades in Q2 2018

Pioneer Investments 203,100 sh (+16.15%)
Vanguard Health Care Fund 2,913,937 sh (unchged)
Jim Simons Sold Out
Leucadia National Sold Out
Ken Fisher 91,844 sh (-4.98%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:PTLA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-06-30 Reduce -4.98%$30.91 - $44.58 $ 21.91-43%91,844
Leucadia National 2018-06-30 Sold Out 0.03%$30.91 - $44.58 $ 21.91-43%0
Vanguard Health Care Fund 2018-03-31 Add 1625.38%0.2%$30.57 - $54.27 $ 21.91-50%2,913,937
Leucadia National 2018-03-31 New Buy0.03%$30.57 - $54.27 $ 21.91-50%15,000
Vanguard Health Care Fund 2017-12-31 New Buy0.02%$47.02 - $55.54 $ 21.91-57%168,887
Ken Fisher 2017-12-31 Add 56.16%$47.02 - $55.54 $ 21.91-57%96,654
Leon Cooperman 2017-12-31 Sold Out 0.1%$47.02 - $55.54 $ 21.91-57%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Portola Pharmaceuticals Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:XMCE:ALM, LSE:GNS, NAS:DNLI, ROCO:4147, NYSE:XON, SZSE:300294, NAS:CORT, SZSE:002287, XKRX:006280, SZSE:002653, NAS:SGMO, NAS:AKCA, NAS:ESPR, NAS:RXDX, NAS:MYOK, NAS:XLRN, NAS:EDIT, XKRX:095700, NAS:SPPI, NYSE:CBM » details
Traded in other countries:0PP.Germany,
Headquarter Location:USA
Portola Pharmaceuticals Inc is engaged in the healthcare sector. It develops & commercializes novel therapeutics to combat thrombosis, hematologic disorders & inflammation.

Portola Pharmaceuticals is a biotechnology company focused on developing and commercializing novel therapeutics. The company focuses on areas of thrombosis, other hematologic disorders, and inflammation for patients who have limited or no approved treatment options. Portola focuses on biomarker or genetic approaches to clinical development that it believes will increase the probability of clinical, regulatory, and commercial success of first-in-class therapies. The company also uses collaborative agreements.

Ratios

vs
industry
vs
history
PB Ratio 6.64
PTLA's PB Ratio is ranked lower than
77% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. PTLA: 6.64 )
Ranked among companies with meaningful PB Ratio only.
PTLA' s PB Ratio Range Over the Past 10 Years
Min: 3.07  Med: 5.33 Max: 34.25
Current: 6.64
3.07
34.25
PS Ratio 58.13
PTLA's PS Ratio is ranked lower than
81% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PTLA: 58.13 )
Ranked among companies with meaningful PS Ratio only.
PTLA' s PS Ratio Range Over the Past 10 Years
Min: 28.57  Med: 97.1 Max: 285.93
Current: 58.13
28.57
285.93
EV-to-EBIT -3.52
PTLA's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. PTLA: -3.52 )
Ranked among companies with meaningful EV-to-EBIT only.
PTLA' s EV-to-EBIT Range Over the Past 10 Years
Min: -14.3  Med: -7.8 Max: -1.3
Current: -3.52
-14.3
-1.3
EV-to-EBITDA -3.55
PTLA's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. PTLA: -3.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
PTLA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.5  Med: -7.9 Max: -1.3
Current: -3.55
-14.5
-1.3
EV-to-Revenue 50.63
PTLA's EV-to-Revenue is ranked lower than
76% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. PTLA: 50.63 )
Ranked among companies with meaningful EV-to-Revenue only.
PTLA' s EV-to-Revenue Range Over the Past 10 Years
Min: 10.3  Med: 83.45 Max: 261.8
Current: 50.63
10.3
261.8
Current Ratio 6.69
PTLA's Current Ratio is ranked higher than
64% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. PTLA: 6.69 )
Ranked among companies with meaningful Current Ratio only.
PTLA' s Current Ratio Range Over the Past 10 Years
Min: 4.94  Med: 7.6 Max: 10.67
Current: 6.69
4.94
10.67
Quick Ratio 6.59
PTLA's Quick Ratio is ranked higher than
64% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. PTLA: 6.59 )
Ranked among companies with meaningful Quick Ratio only.
PTLA' s Quick Ratio Range Over the Past 10 Years
Min: 4.94  Med: 7.57 Max: 10.67
Current: 6.59
4.94
10.67
Days Inventory 462.74
PTLA's Days Inventory is ranked lower than
92% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. PTLA: 462.74 )
Ranked among companies with meaningful Days Inventory only.
PTLA' s Days Inventory Range Over the Past 10 Years
Min: 462.74  Med: 483.3 Max: 483.3
Current: 462.74
462.74
483.3
Days Sales Outstanding 51.42
PTLA's Days Sales Outstanding is ranked higher than
63% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. PTLA: 51.42 )
Ranked among companies with meaningful Days Sales Outstanding only.
PTLA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.16  Med: 7.59 Max: 60.71
Current: 51.42
2.16
60.71
Days Payable 1.00
PTLA's Days Payable is ranked lower than
98% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. PTLA: 1.00 )
Ranked among companies with meaningful Days Payable only.
PTLA' s Days Payable Range Over the Past 10 Years
Min: 1  Med: 8183.04 Max: 8183.04
Current: 1
1
8183.04

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.20
PTLA's 3-Year Average Share Buyback Ratio is ranked higher than
59% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. PTLA: -10.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PTLA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -30.4  Med: -17.2 Max: -10.2
Current: -10.2
-30.4
-10.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 10.24
PTLA's Price-to-Net-Cash is ranked lower than
69% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. PTLA: 10.24 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PTLA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.52  Med: 6.87 Max: 43.21
Current: 10.24
3.52
43.21
Price-to-Net-Current-Asset-Value 7.85
PTLA's Price-to-Net-Current-Asset-Value is ranked lower than
66% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. PTLA: 7.85 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PTLA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.3  Med: 6.68 Max: 35.55
Current: 7.85
3.3
35.55
Price-to-Tangible-Book 6.87
PTLA's Price-to-Tangible-Book is ranked lower than
71% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. PTLA: 6.87 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PTLA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.14  Med: 5.5 Max: 31.45
Current: 6.87
3.14
31.45
Price-to-Median-PS-Value 0.60
PTLA's Price-to-Median-PS-Value is ranked higher than
61% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. PTLA: 0.60 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PTLA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36  Med: 1.01 Max: 2.28
Current: 0.6
0.36
2.28
Earnings Yield (Greenblatt) % -28.61
PTLA's Earnings Yield (Greenblatt) % is ranked lower than
71% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. PTLA: -28.61 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PTLA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -76.3  Med: -12.8 Max: -7
Current: -28.61
-76.3
-7

More Statistics

Revenue (TTM) (Mil) $24.29
EPS (TTM) $ -5.73
Beta1.93
Volatility38.08%
52-Week Range $21.66 - 56.70
Shares Outstanding (Mil)66.09

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 32 150 243 532
EBIT (Mil $) -368 -294 -295
EBITDA (Mil $) -366 -292 -293
EPS ($) -5.71 -2.85 -1.57 2.43
EPS without NRI ($) -5.71 -2.85 -1.57 2.43
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}